VA
VR Adviser Portfolio holdings
AUM
$1.33B
This Quarter Return
+33.89%
1 Year Return
+6.92%
3 Year Return
+862.77%
5 Year Return
+1,580.48%
10 Year Return
–
AUM
$680M
AUM Growth
+$680M
(+33%)
Cap. Flow
+$44.7M
Cap. Flow
% of AUM
6.57%
Top 10 Holdings %
Top 10 Hldgs %
79.62%
Holding
31
New
9
Increased
4
Reduced
4
Closed
6
Top Buys
| 1 |
Olema Pharmaceuticals
OLMA
|
$73.9M |
| 2 |
KNTE
Kinnate Biopharma Inc. Common Stock
KNTE
|
$58.6M |
| 3 |
VistaGen Therapeutics
VTGN
|
$18.2M |
| 4 |
MRNS
Marinus Pharmaceuticals, Inc
MRNS
|
$17M |
| 5 |
Aclaris Therapeutics
ACRS
|
$12.6M |
Top Sells
| 1 |
TRIL
Trillium Therapeutics Inc.
TRIL
|
$46.6M |
| 2 |
Cogent Biosciences
COGT
|
$36.7M |
| 3 |
SURF
Surface Oncology, Inc. Common Stock
SURF
|
$22.5M |
| 4 |
Cardiff Oncology
CRDF
|
$18M |
| 5 |
IMV
IMV Inc. Common Shares
IMV
|
$17.8M |
Sector Composition
| 1 | Healthcare | 86.62% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
CNST
1
DELISTED
Constellation Pharmaceuticals, Inc.
CNST
| $116M | 17.01% | 4,016,873 | – | – |
|
|
2
Olema Pharmaceuticals
OLMA
$375M
| $73.9M | 10.86% | +1,536,193 | New | +$73.9M |
|
|
TRIL
3
DELISTED
Trillium Therapeutics Inc.
TRIL
| $59.4M | 8.74% | 4,040,000 -3,164,577 | -44% | -$46.6M |
|
|
KNTE
4
DELISTED
Kinnate Biopharma Inc. Common Stock
KNTE
| $58.6M | 8.62% | +1,473,014 | New | +$58.6M |
|
5
Athira Pharma
ATHA
$15.3M
| $57.9M | 8.52% | 1,691,623 +170,000 | +11% | +$5.82M |
|
6
Altimmune
ALT
$338M
| $50.8M | 7.46% | 4,500,000 | – | – |
|
7
Keros Therapeutics
KROS
$618M
| $47.4M | 6.97% | 672,306 | – | – |
|
|
MRNS
8
DELISTED
Marinus Pharmaceuticals, Inc
MRNS
| $31.6M | 4.64% | 2,588,941 +1,396,058 | +117% | +$17M |
|
9
Syndax Pharmaceuticals
SNDX
$1.41B
| $24.8M | 3.65% | 1,115,255 +489,545 | +78% | +$10.9M |
|
10
Relmada Therapeutics
RLMD
$37.2M
| $21.4M | 3.15% | 668,440 | – | – |
|
11
Kura Oncology
KURA
$686M
| $18.8M | 2.76% | 575,000 | – | – |
|
|
12
VistaGen Therapeutics
VTGN
$102M
| $18.2M | 2.67% | +9,360,000 | New | +$18.2M |
|
13
Celldex Therapeutics
CLDX
$1.47B
| $14M | 2.06% | 800,000 | – | – |
|
|
SURF
14
DELISTED
Surface Oncology, Inc. Common Stock
SURF
| $13.3M | 1.96% | 1,442,895 -2,435,000 | -63% | -$22.5M |
|
|
15
Aclaris Therapeutics
ACRS
$209M
| $12.6M | 1.86% | +1,954,932 | New | +$12.6M |
|
|
16
Cogent Biosciences
COGT
$1.69B
| $12.2M | 1.8% | 1,088,817 -3,266,456 | -75% | -$36.7M |
|
17
Aligos Therapeutics
ALGS
$73.3M
| $11.2M | 1.65% | +404,906 | New | +$11.2M |
|
|
GRTX
18
DELISTED
Galera Therapeutics, Inc. Common Stock
GRTX
| $9.39M | 1.38% | 917,860 +866,207 | +1,677% | +$8.86M |
|
19
ARS Pharmaceuticals
SPRY
$1.15B
| $6.95M | 1.02% | +150,000 | New | +$6.95M |
|
20
Tango Therapeutics
TNGX
$747M
| $5.72M | 0.84% | 500,000 | – | – |
|
|
MTCR
21
DELISTED
Metacrine, Inc. Common Stock
MTCR
| $5.45M | 0.8% | 693,673 -450,000 | -39% | -$3.54M |
|
|
FPRX
22
DELISTED
Five Prime Therapeutics, Inc.
FPRX
| $4.17M | 0.61% | +245,122 | New | +$4.17M |
|
23
BioAtla
BCAB
$26.7M
| $3.4M | 0.5% | +100,000 | New | +$3.4M |
|
24
Taysha Gene Therapies
TSHA
$797M
| $2.87M | 0.42% | 107,982 | – | – |
|
25
Viridian Therapeutics
VRDN
$1.5B
| $321K | 0.05% | +19,495 | New | +$321K |
|